Express Mailing Label No. EJ69 6847US Date of Deposit: September 28, 1999



[1-27] #1

PATENT APPLICATION Attorney Docket No. 00960-515 (CRP-145)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**APPLICANTS**:

Cohen, et al.

ASSIGNEE:

Creative BioMolecules, Inc.

SERIAL NUMBER:

08/851,628

**EXAMINER:** 

Romeo, D.

FILING DATE:

May 6, 1997

ART UNIT:

1646

FOR:

NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

Assistant Commissioner for Patents Washington, D.C. 20231

## REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

CREATIVE BIOMOLECULES, INC., a company and owner of the above-identified United States patent application U.S.S.N. 08/851,628, filed May 6, 1997, assignment recorded on November 28, 1997, at Reel 8827/Frame 0589, hereby revokes any and all former powers of attorney and appoints:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
David B. Bernstein	32,112	John T. Prince	43,091
David F. Crosby	36,400	Brian Rosenbloom	41,276
Brett N. Dorny	35,8\$0	Thomas M. Sullivan	39,392
Ivor R. Elrifi	39,5 <b>2</b> 9	Howard Susser	33,586
John A. Harre	37,3 <b>4</b> 5	Martin M. Zoltick	35,745
William Marino	44,219	Kristin E. Konzak	P-44,848
Leslie Meyer-Leon	37,381	Carol H. Peters	P-45,010
A. Jason Mirabito	28,161	Garfield B. Simms	P-45,109
Michel Morency	Limited Recognition	Shelby J. Walker	P-45,192

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

APPLICATION NO.
APPLICANTS:

08/851,628 Cohen, et al.

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Ivor R. Elrifi

Ivor R. Elrifi, or

Mintz Levin

Michel Morency

One Financial Center

(617) 542-6000

Boston, MA 02111

CREATIVE BIOMOLECULES, INC. certifies under 37 C.F.R. § 3.73(b) that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of assignments of the above identified patent.

I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the patent.

Please charge any fee or any fee deficiency occasioned by this document to Deposit Account No. 50-0311.

Respectfully submitted,

Cheryl Lawton

Vice President, General Counsel

CREATIVE BIOMOLECULES, INC.

Sor. Date: August 10, 199

TRADOCS: 1235307.1 (qh6301!.doc)



## BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

## LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Michel Morency is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. to prepare and prosecute patent applications wherein (1) Michel Morency represents only clients of the Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. law firm, and (2) wherein a member of the Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. law firm who, in turn, is a registered patent attorney or agent, is the attorney or agent of record in the applications. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Michel Morency ceases to lawfully reside in the United States, (ii) Michel Morency's employment with Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. ceases or is terminated, or (iii) Michel Morency ceases to remain or reside in the United States on H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: January 1, 2000

Karen L. Bovard, Director

Office of Enrollment and Discipline

Express Mailing Label No. EJ695376847US Attorney Reference No. 00960-515 (CRP-145)